Skip to content

Dyskeratosis Congenita Autosomal Recessive 7 C4225283

Published: July 22, 2026Updated: August 20, 2026

A rare inherited bone marrow failure disorder causing abnormal skin pigmentation, nail changes, and oral patches. Primarily inherited through autosomal recessive patterns. Management focuses on symptom relief and bone marrow transplant for severe cases.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Hematopoietic Stem Cell Transplantation

HSCT represents the definitive treatment for bone marrow failure manifestations in autosomal recessive dyskeratosis congenita subtype 7. Advances in transplant techniques have improved survival outcomes.

procedure
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Cancer Surveillance Program

Enhanced surveillance for head and neck squamous cell carcinoma, anogenital carcinoma, and other malignancies associated with dyskeratosis congenita through regular examinations and imaging.

monitoring

Additional treatment options

Immunomodulatory Therapy

Low-dose corticosteroids or other immunomodulatory agents may be considered for select patients with autoimmune cytopenias complicating bone marrow failure.

medication

Oral Hygiene Protocol

Intensive oral care including regular dental visits, antimicrobial mouthwashes, and treatment of oral leukoplakia reduces risk of malignant transformation and infection.

dietary

Psychosocial Support Services

Mental health support addressing chronic illness burden, body image concerns related to mucocutaneous manifestations, and family stress through individual and family counseling.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dyskeratosis Congenita Autosomal Recessive 7 C4225283?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dyskeratosis Congenita Autosomal Recessive 7 C4225283. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy